Precision Phenotyping in Cardiometabolic Medicine: Genetic Susceptibility of Diabetes Subtypes and Coronary Artery Disease Risk
Posted inCardiology Clinical Updates Diabetes & Endocrinology news

Precision Phenotyping in Cardiometabolic Medicine: Genetic Susceptibility of Diabetes Subtypes and Coronary Artery Disease Risk

This review synthesizes evidence on the genetic architecture of adult-onset diabetes subtypes, highlighting that Moderate Obesity-related Diabetes (MOD) is uniquely and causally linked to coronary artery disease risk through polygenic and Mendelian randomization analyses.
Beyond a Uniform Approach: Data-Driven Phenotyping Reveals High-Risk Clusters in Gestational Diabetes Mellitus
Posted inDiabetes & Endocrinology news

Beyond a Uniform Approach: Data-Driven Phenotyping Reveals High-Risk Clusters in Gestational Diabetes Mellitus

A groundbreaking machine learning study of over 37,000 patients identifies four distinct GDM phenotypic clusters. These findings demonstrate that early-diagnosed, high-comorbidity phenotypes carry a four-fold increased risk of postpartum diabetes, signaling a need for personalized clinical management in obstetric care.
Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care
Posted inAllergy & Immunology Clinical Updates news Respiratory

Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care

This review analyzes findings from the pan-European SHARP registry study, identifying distinct multimorbidity phenotypes in severe asthma. It highlights the impact of steroid-associated and sinonasal clusters on clinical outcomes, advocating for a holistic approach to complex patient management.
Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D
Posted inDiabetes & Endocrinology Internal Medicine news

Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D

A post-hoc analysis demonstrates that baseline insulin secretion identifies responders to abatacept in Stage 1 T1D. High-secretors experienced a 15.8-month delay in disease progression and a 54% reduction in risk, providing the first evidence of successful immune intervention in the earliest stage of the disease.